Oxurion NV – Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149 augustus 16, 20210OpmerkingenEN Read More
Tussentijdse halfjaarresultaten 30 juni 2021 juni 30, 20210OpmerkingenTussentijdse halfjaarresultaten 30 juni 2021 Read More
Interim Financial Report Half-year results as of June 30, 2021 juni 30, 20210OpmerkingenInterim Financial Report Half-year results as of June 30, 2021 Read More
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149 juni 25, 20210OpmerkingenEN Read More
OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) juni 10, 20210OpmerkingenEN Read More
OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) juni 8, 20210OpmerkingenEN Read More
OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting april 30, 20210OpmerkingenEN Read More
OXURION NV to Present at Wet AMD and DME Drug Development Summit april 13, 20210OpmerkingenEN Read More
Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD april 7, 20210OpmerkingenEN Read More
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group april 6, 20210OpmerkingenEN Read More
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer januari 20, 20210OpmerkingenEN Read More
Jaarrapport – financiële informatie 2020 december 30, 20200OpmerkingenJaarrapport - financiële informatie 2020 Read More
Annual Report – Financial Information 2020 december 30, 20200OpmerkingenAnnual Report - Financial Information 2020 Read More
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices november 9, 20200OpmerkingenEN Read More
